Key result
Nirmatrelvir-ritonavir strongly inhibits CYP3A4 and P-glycoprotein, causing significant drug-drug interactions with many cardiovascular medications that require dose adjustment or temporary withholding.
Why the study?
Patients with cardiovascular risk factors and cardiovascular disease treated with nirmatrelvir-ritonavir for COVID-19 are at risk of significant drug-drug interactions with cardiovascular medications due to ritonavir's CYP450 inhibition.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The clinical community should be aware that there is a potential for serious interaction when Paxlovid is prescribed for people on cardiovascular medications. Having said that, it's not a reason to deter people from prescribing Paxlovid.”
“Awareness of the presence of drug-drug interactions of Paxlovid with common cardiovascular drugs is key. System-level interventions by integrating drug-drug interactions into electronic medical records could help avoid related adverse events.”
Provides a practical, mechanism-based clinical decision-making algorithm for safely managing drug-drug interactions between nirmatrelvir-ritonavir and commonly prescribed cardiovascular medications.
Nirmatrelvir-ritonavir (NMVr) is used to treat symptomatic, nonhospitalized patients with coronavirus disease-2019 (COVID-19) who are at high risk of progression to severe disease. Patients with cardiovascular risk factors and cardiovascular disease are at a high risk of developing adverse events from COVID-19 and as a result have a higher likelihood of receiving NMVr. Ritonavir, the pharmaceutical enhancer used in NMVr, is an inhibitor of the enzymes of CYP450 pathway, particularly CYP3A4 and to a lesser degree CYP2D6, and affects the P-glycoprotein pump. Co-administration of NMVr with medications commonly used to manage cardiovascular conditions can potentially cause significant drug-drug interactions and may lead to severe adverse effects. It is crucial to be aware of such interactions and take appropriate measures to avoid them. In this review, we discuss potential drug-drug interactions between NMVr and commonly used cardiovascular medications based on their pharmacokinetics and pharmacodynamic properties.
No takes yet. Share an insight, caveat, or question.
Abraham et al. (2022) conducted a review in Cardiovascular disease and COVID-19. Nirmatrelvir-ritonavir (NMVr) co-administered with cardiovascular medications was evaluated on Drug-drug interactions and associated adverse effects with cardiovascular medications. Nirmatrelvir-ritonavir strongly inhibits CYP3A4 and P-glycoprotein, causing significant drug-drug interactions with many cardiovascular medications that require dose adjustment or temporary withholding.
Synapse has enriched 10 related papers. Consider them for comparative context: